Emd Serono Research & Development Institute, Inc.

This early-stage study tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety and find the right dose, wh…

This study tests an experimental drug called M9140 in people with advanced solid tumors (stomach, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a powerful chemotherapy directly to cancer cells. The goal is to see if it can shr…

This early-stage study tests a new drug called M0324 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells and boost the immune system. Researchers will test M0324 alone, with another immunotherapy (pembro…

This study tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has not responded to prior therapies. About 1,020 adults who have already tried up to two prior treatments will participate. T…

This study tests a new pill, enpatoran, for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can reduce skin disease severity and …

This early-phase study tests a new drug called M3554 in people with advanced solid tumors, specifically soft tissue sarcoma and a type of brain cancer (glioblastoma). The main goal is to find a safe dose and check for side effects. About 52 participants will receive the drug intr…

This early-stage study tests a new drug called M9140 in people with advanced colorectal cancer that has not responded to standard treatments. The drug works like a guided missile, delivering a cancer-killing agent directly to tumor cells. The main goals are to find a safe dose an…

This study tests an experimental drug called enpatoran for people with lupus that causes active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if the drug reduces skin disease…

This study is a disease registry that collects information from about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will track which treatments patients receive, how well they work, and any side effects…